Spruce Biosciences Inc expected to post a loss of 21 cents a share - Earnings Preview

Spruce Biosciences

11/04/2025 12:06

Spruce Biosciences Inc SPRB.OQ SPRB.O is expected to show a fall in quarterly revenue when it reports  results on April 14 (estimated) for the period ending December 31 2024

The South San Francisco California-based  company is expected to report a 69.3% decrease in revenue to $885 thousand from $2.89 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Spruce Biosciences Inc is for a loss of 21 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 5 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Spruce Biosciences Inc is $1.50​, above​ its last closing price of $0.30. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.23
-0.24
-0.21
Beat
11.6
Jun. 30 2024
-0.32
-0.32
-0.22
Beat
31.4
Mar. 31 2024
-0.29
-0.29
-0.28
Beat
3.2​
Dec. 31 2023
-0.39
-0.39
-0.24
Beat
37.8
​​Sep. 30 2023
-0.36
-0.35
-0.30
Beat
15.1
Jun. 30 2023
-0.39
-0.39
-0.32
Beat
18.4​
Mar. 31 2023
-0.33
-0.36
-0.40
Missed
-10.4
Dec. 31 2022
-0.56
-0.53
-0.47
Beat
11.3

This summary was machine generated April 11 at 11:06 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)